TriangleFOR PATIENTS · SOURCE READING
Treatment of LCH is based on where LCH cells are found in the body and whether the LCH is low risk or high risk.
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
LCH is described as single-system disease or multisystem disease, depending on how many body systems are affected:
Single-system LCH: LCH is found in one part of an organ or body system or in more than one part of that organ or body system. Bone is the most common single place for LCH to be found.
Source links and citations
Multisystem LCH: LCH is found in two or more organs or body systems or may be found throughout the body. Multisystem LCH is less common than single-system LCH.
LCH may affect low-risk organs or high-risk organs:
Low-risk organs include the skin, bone, lungs, lymph nodes, gastrointestinal tract, pituitary gland, thyroid gland, thymus, and central nervous system (CNS).
Source links and citations
High-risk organs include the liver, spleen, and bone marrow.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice